

IN THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-10 (canceled).

Claim 11 (currently amended): A pressurized metered dose inhaler, said inhaler containing a solution comprising an active ingredient, a hydrofluorocarbon propellant, and a cosolvent, wherein said inhaler has an internal surface and all or part of said internal surface is a material selected from the group consisting of stainless steel and anodized aluminum.

Claim 12 (previously presented): The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component.

Claim 13 (previously presented): The pressurized metered dose inhaler of Claim 12, wherein said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate.

Claim 14 (previously presented): The pressurized metered dose inhaler of Claim 11, wherein said active ingredient is selected from the group consisting of  $\beta_2$  agonists, steroids, anticholinergic agents, and mixtures thereof.

Claim 15 (currently amended): The pressurized metered dose inhaler of Claim 11, wherein said active ingredient is selected from the group consisting of a  $\beta$ -adrenergic agonist, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide,

U.S. Patent Application No. 09/831,888  
Reply to Office Action dated February 13, 2007

triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof.

Claim 16 (previously presented): The pressurized metered dose inhaler of Claim 11, wherein said co-solvent is ethanol.

Claim 17 (previously presented): The pressurized metered dose inhaler of Claim 11, wherein said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof.

Claims 18-19 (canceled).

Claim 20 (currently amended): The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component; said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate; said active ingredient is selected from the group consisting of a  $\beta$ -adrenergic agonists agonist, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof; said co-solvent is ethanol; and said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof; and part or all of said internal surface is stainless steel.

Claim 21 (previously presented): The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is ipratropium bromide.

Claim 22 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is oxitropium bromide.

Claim 23 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is tiotropium bromide.

Claim 24 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is flunisolide.

Claim 25 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is triamcinolone acetonide.

Claim 26 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is fluticasone propionate.

Claim 27 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is mometasone furoate.

Claim 28 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is budesonide.

Claim 29 (previously presented): The pressurized metered dose inhaler of Claim 20,  
wherein said active ingredient is ciclesonide.

Claim 30 (previously presented): The pressurized metered dose inhaler of Claim 20, wherein said active ingredient is rofleponide.

Claim 31 (currently amended): The pressurized metered dose inhaler of Claim 11, wherein said solution further comprises a low-volatility component; said low-volatility component is selected from the group consisting of propylene glycol, glycerol, polyethylene glycol, and isopropyl myristate; said active ingredient is selected from the group consisting of a β-adrenergic agonists agonist, ipratropium bromide, oxitropium bromide, tiotropium bromide, flunisolide, triamcinolone acetonide, fluticasone propionate, mometasone furoate, budesonide, ciclesonide, rofleponide, and epimers thereof; and said co-solvent is ethanol; ~~said propellant is selected from the group consisting of HFA 227, HFA 134a, and mixtures thereof; and part or all of said internal surface is anodized aluminum.~~

Claim 32 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is ipratropium bromide.

Claim 33 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is oxitropium bromide.

Claim 34 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is tiotropium bromide.

Claim 35 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is flunisolide.

Claim 36 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is triamcinolone acetonide.

Claim 37 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is fluticasone propionate.

Claim 38 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is mometasone furoate.

Claim 39 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is budesonide.

Claim 40 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is ciclesonide.

Claim 41 (previously presented): The pressurized metered dose inhaler of Claim 31, wherein said active ingredient is rofleponide.

Claim 42 (currently amended): The pressurized metered dose inhaler of Claim 15, wherein said active  $\beta$ -adrenergic agonist is selected from the group consisting of salbutamol, formoterol, salmeterol, and TA 2005.

Claim 43 (currently amended): The pressurized metered dose inhaler of Claim 20, wherein said active  $\beta$ -adrenergic agonist is selected from the group consisting of salbutamol, formoterol, salmeterol, and TA 2005.

Claim 44 (currently amended): The pressurized metered dose inhaler of Claim 31,  
wherein said **active**  $\beta$ -adrenergic agonist is selected from the group consisting of salbutamol,  
formoterol, salmeterol, and TA 2005.